Author: Ken Dropiewski

NEWS RELEASE Biosensors Announces Enrollment of the First American Patient in the new US Pivotal BioFreedom Trial – “LEADERS FREE II”

Press Release Singapore, 22 March 2017 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”), a developer, manufacturer and marketer of innovative medical devices, announced today the enrollment of the first American patient in LEADERS FREE II, its new BioFreedom […]

Metactive Medical Announces Issuance of Patents on Blockstent and Ballstent Embolization Devices

OLATHE, Kan.–(BUSINESS WIRE)–Metactive Medical Inc. (Metactive), an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced the issuance of US Patents 9,572,697 and 9,572,698 covering its Ballstent Microcatheter™ for embolization of […]

Humacyte Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Expedited Review Designation for HUMACYL® in Vascular Access for Hemodialysis

Press Release RESEARCH TRIANGLE PARK, N.C. — Humacyte, an innovator in biotechnology and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted HUMACYL®, its investigational human acellular vessel (HAV), the Regenerative Medicine Advanced Therapy (RMAT) […]

Biosense Webster Launches CARTO® 3 System CARTO VISITAG™ Module with Ablation Index, designed to help Electrophysiologists standardize and simplify the treatment of Atrial Fibrillation

DIAMOND BAR, California, March 22, 2017 /PRNewswire/ — Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today the launch of the CARTO VISITAG™ Module with Ablation […]

New Meta-Analysis Presented at American College of Cardiology Strongly Supports RenalGuard(R) Use in Cardiovascular Interventional Procedures

MILFORD, MA — (Marketwired) — 03/22/17 — A new meta-analysis presented this week at the American College of Cardiology further supports the ability of RenalGuard Therapy® to significantly reduce the incidence of acute kidney injury associated with cardiovascular interventional procedures […]

Arrhythmia Research Technology, Inc. Reports 2016 Fourth Quarter and Year End Results

FITCHBURG, Mass., March 22, 2017 (GLOBE NEWSWIRE) — Arrhythmia Research Technology, Inc. (NYSE MKT:HRT) (the “Company”), through its wholly-owned subsidiary, Micron Products, Inc., a diversified contract manufacturing organization that produces highly-engineered, innovative medical device components requiring precision machining and injection […]